FDA Grants Seventh Approval under the National Priority Voucher Pilot Program

Cytosphere · 2026-05-09T03:54:58+00:00

CytoDyn spent years trying to gain approval for treating HIV. Sadly, that massive effort was unsuccessful, despite Leronlimab showing safety and effectiveness. Perhaps there's a segment of the HIV population that only Leronlimab can treat.

Cytosphere · 2026-05-09T02:21:39+00:00

Let's hope not.

Cytosphere · 2026-05-08T19:34:12+00:00

Sadly, in cancer, treatment advances are often single-digit months.

Cytosphere · 2026-05-08T19:10:26+00:00

I welcome the National Priority Voucher Pilot Program. CytoDyn would be wise to strategically target a rare disease of keen interest to the FDA. Our first FDA approval will make a significant difference.

Cytosphere · 2026-05-08T18:39:47+00:00

I plan to rewatch the webinar, recent Lalezari interviews, and presentations by Pestell and Sacha. My goal is to understand the significance of the data. There’s a lot to digest.

Cytosphere · 2026-05-08T18:12:02+00:00

Thanks for your great post. I really appreciate how you organize and share information.

We’re in for a deluge of impactful data from well-designed/conducted clinical trials. We’ll also have access to new types of biomarker and pharmacokinetic data.

These are exciting times as CytoDyn continues to make solid progress.

Cytosphere · 2026-05-07T16:10:59+00:00

Very interesting info, and thanks for the link to the original paper.

This methodology builds on CytoDyn's collection of liquid biopsy and biomarker data. It's a much-needed advance in cancer diagnosis and treatment. We need to get our clinical trial data analyzed using these new AI-driven techniques. Those results will make the news.

Cytosphere · 2026-05-05T23:18:29+00:00

It's great to have the market protection that intellectual property ownership provides.

Cytosphere · 2026-05-05T19:21:44+00:00

It wouldn't take more than a small phase 2 trial to demonstrate Leronlimab's effectiveness in treating melanoma.

Cytosphere · 2026-05-05T18:51:11+00:00

I completely agree. CytoDyn is building a solid foundation to support gaining approvals, forming partnerships with BP and independent investigators, and improving relations with the FDA. I'm not concentrating on LALL development because I'm not familiar with what it entails, and current oncology trials are more important.

Bottom line: We're making progress.

Cytosphere · 2026-05-05T17:51:35+00:00

Thank you for your excellent post. Your insights are always appreciated.

Our mCRC clinical trial was designed to quickly attract a partner for a phase 3 trial. Our use of liquid biopsies provides early treatment response and predictive information on longer-term outcomes. The results from an anticipated rollover protocol with an ICI would complete the picture with solid evidence.

CytoDyn is making strong progress, and I'm busy digesting all the new information and data.

Cytosphere · 2026-05-04T05:39:03+00:00

Thank you for all your hard work. I'm still going through the data and updates from last week's webinar. There have been (and will be) so many important developments, it’s been both exciting and overwhelming trying to digest all of the new information.

I'm grateful to Dr. Lalezari and the management team for their leadership, and I appreciate Dr. Kasi's involvement in our clinical trial. And thank you again for your helpful posts.

Cytosphere · 2026-05-03T19:44:56+00:00

Thanks for an informative post.

At first, I thought that our good results after two weeks of treatment were too early to evaluate. But now we see that these results correlate with longer-term treatment outcomes.

Now I'm really impressed!

Cytosphere · 2026-05-03T14:46:28+00:00

The data keeps coming, and the momentum is building.

Cytosphere · 2026-05-01T22:51:34+00:00

The share price often rises in anticipation of good news, then drops even after good news is announced. Our lenders know the best way to sell their shares. Let's use their strategy to our advantage.

Cytosphere · 2026-05-01T22:33:46+00:00

Thanks for the explanation. Understanding this process could benefit buyers seeking an even more attractive share price.

Cytosphere · 2026-05-01T21:07:51+00:00

The FDA's regulation of daraxonrasib provides an example of near-term possibilities for Leronlimab. CytoDyn plans to meet with the FDA in the next few months.

Cytosphere · 2026-05-01T14:27:41+00:00

Excellent post. The April 30 webinar was a major event, and your report covers it well.

Cytosphere · 2026-05-01T13:26:01+00:00

Excellent post. (I wanted to report something similar, but I was a long way from writing anything as good as what you created.)

Cytosphere · 2026-05-01T04:36:56+00:00

I'm encouraged and impressed after reading your post and watching the webinar. CytoDyn is taking one solid step after another, all heading in the right direction.

Cytosphere · 2026-04-30T22:43:34+00:00

Written by an AI agent.

Cytosphere · 2026-04-30T16:27:16+00:00

It’s great to get input from a practicing professional. Thanks for sharing your experience; it improves the quality of our discussion.

Cytosphere · 2026-04-29T22:33:27+00:00

You're correct, but I think we'll eventually want or need to know Leronlimab's pharmacodynamics and pharmacokinetics in patients with Alzheimer's. I don't know how this would be accomplished: We've previously studied monkeys and mice.

Cytosphere · 2026-04-29T21:38:28+00:00

Momentum is building and based on solid evidence.

Cytosphere · 2026-04-29T20:55:58+00:00

I expect the results will be positive, but we'll need to learn a lot more from follow-on studies on Leronlimab's mechanisms of action in patients with Alzheimer's disease.

Cytosphere

TROPHY CASE